FDA accepts BLA for Alder's migraine therapy for infusion

Alder said FDA accepted a BLA for eptinezumab to prevent migraine. The company, which submitted the BLA on Feb. 21, said it expects to receive a PDUFA date within 74 days following the submission.

If approved, Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) plans to launch the mAb against calcitonin gene-related peptide (CGRP) in 1Q20...